[1] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[2] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[3] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[4] |
WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong.
Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
|
[5] |
CHEN Manxin, ZHANG Bingyu, DAI Min.
Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
|
[6] |
FENG Zhuangzhuang, SONG Ruiping, DOU Pengcheng, CHEN Xinyi, ZUO Jiaojiao, SHU Jin.
Effect of Zhiwei Fuwei Pills on autophagy in gastric antrum tissue of rats with precancerous lesions of gastric cancer based on mTOR/Beclin1/LC3 signaling axis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 361-370.
|
[7] |
NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang.
Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
|
[8] |
SHEN Jiaqing, LIU Yi.
Mechanism of tyrosine kinase 2 inhibitors in treatment of plaque psoriasis and their progress in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 323-330.
|
[9] |
WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei.
Research progress on pathogenic fusion gene in lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.
|
[10] |
DUAN Ruixiao, ZHAO Yifan, YE Yongjuan, LIU Min, LI Qiang, ZHOU Yongning.
Mechanism of action of bile acid metabolism in regulating inflammatory bowel disease and the research and development of drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1171-1181.
|
[11] |
CHEN Yunjie, ZHOU Xuan, ZHANG Yuanbin, WANG Xu, LIN Zhu, ZHU Suyan.
Reseach progress on the role of ErbB2 in cardiac disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1182-1189.
|
[12] |
CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin.
Advances in the study of iodine-resistant differentiated thyroid cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
|
[13] |
LIU Chen, FANG Mengdie, XU Hao, LI Chao, REN Juan, ZUO Bowen, ZHANG Yanmei.
Atractyloside targets the area of action of oncoprotein BORIS to inhibit cancer cell proliferation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1005-1013.
|
[14] |
HAO Haiping.
Metabolic regulation and drug target discovery researches in China: Progress and prospect
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 955-963.
|
[15] |
CHEN Ying, YUAN Yonggui.
Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
|